

**ASX/Media Release**

**27 February 2017**

**Botanix Announces Filing of New Permetrex™ Product Patents**

- Botanix filed new patent applications covering new Permetrex™ enabled products
- New products include additional uses for synthetic cannabidiol in different skin diseases
- Additional products also include complementary skin products that can be rapidly developed and commercialised

**Philadelphia PA, 27 February 2017:** Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or “The Company”) today announced that it has filed 5 new patent applications covering Permetrex enabled products.

The new patent applications include additional uses for the Company’s drug active, synthetic cannabidiol in different skin diseases outside acne, as well as additional products targeted at complementary skin care. Permetrex is the delivery technology utilised for the Company’s lead acne treatment, BTX-1503, which is progressing rapidly through clinical development. The new patent applications were filed simultaneously in the US and Australia.

The first human study involving Permetrex was completed in December 2016 and showed that the skin delivery technology was safe and had minimal irritancy potential. Permetrex provides a more effective way of delivering drugs that does not use chemicals that dry out the skin, and which does not require the use of preservatives that can cause serious allergic reactions. As many existing dermatology products use sub-optimal formulations that suffer from these limitations, a range of marketed skin disease drugs can be substantially improved utilizing the Permetrex approach.

“After rapid development work over the last several months, we have identified a number of new uses for synthetic cannabidiol which are supported by scientific literature and which could be enabled by the Permetrex delivery system”, Botanix Executive Director, Matt Callahan commented.

“With a proof of concept formulation in hand, we have taken steps to protect these new products while we continue development and commercialisation planning.”

Botanix announced an expansion of its license to use Permetrex in early February, thereby enabling the Company to use the delivery technology for a much wider range of drugs already approved by the FDA, as well as new drugs for treating skin disease. Some of the new patent applications are aimed at protecting new formulations of currently approved actives, which can potentially be developed quickly and commercialised without the need to submit the new products for regulatory agency approval. Botanix plans to undertake limited early stage development work on some of these products opportunities in the coming months.

## About Botanix Pharmaceuticals

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy in 1H 2017 and plans to progress the development of its pipeline of other Permetrex enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit [www.botanixpharma.com](http://www.botanixpharma.com) or follow us on Twitter @Botanixpharma.

### For more information, please contact:

#### General enquiries

Matt Callahan  
Botanix Pharmaceuticals Ltd  
Executive Director  
P: +1 215 767 4184  
E: [mcallahan@botanixpharma.com](mailto:mcallahan@botanixpharma.com)

#### Investor Relations

Ben Walsh  
WE Buchan  
P: (02) 9237 2801  
E: [bwalsh@buchanwe.com.au](mailto:bwalsh@buchanwe.com.au)

#### Media enquiries

Arthur Chan  
WE Buchan  
P: (02) 9237 2805  
E: [achan@buchanwe.com.au](mailto:achan@buchanwe.com.au)